NK cells are innate immune lymphocytes involved in controlling microbial infections, tumor immunosurveillance, hematopoietic allograft rejection, and pregnancy ([@bib59]; [@bib48]; [@bib60]). NK cell effector functions include direct cytotoxicity and production of the cytokines (e.g., IFN-γ) and chemokines involved in the regulation of immune responses. NK cell activation is regulated by an array of activating and inhibitory cell surface receptors, which can detect nonself ligands or changes in the expression of self-molecules on infected or abnormal cells. NK cells were originally identified on the basis of their ability to lyse tumor cells without prior sensitization, but multiple mechanisms underlie the acquisition of their full effector functions ([@bib42]; [@bib18]; [@bib46]; [@bib48]; [@bib60]). MHC class I molecule (MHC-I) recognition by inhibitory receptors expressed on NK cells participates in the acquisition of NK cell responsiveness. Indeed, NK cells lacking self-MHC-I--specific inhibitory receptors and NK cells from MHC-I--deficient humans or mice are hyporesponsive to activating receptor stimulation ([@bib25]; [@bib35]; [@bib2]; [@bib51]; Brodin et al., 2009a,b; [@bib28]). This process, referred as to NK cell MHC-I--dependent education, ensures self-tolerance and immunocompetence. In addition, NK cells must be primed with cytokines, such as IL-15, IL-12, and IL-18, and by interactions with accessory cells, to achieve their full effector potential ([@bib48]; [@bib60]). In particular, activated DCs have been shown to prime NK cells by trans-presenting IL-15 on their IL-15Rα ([@bib38]). Interactions between NK cells and monocytes or macrophages have also been shown to be required for correct NK cell activation ([@bib16]; [@bib4]; [@bib61]; [@bib45]; [@bib58]; [@bib6]; [@bib54]). These mechanisms help to adapt NK cell function to the host environment, ensuring appropriate and regulated NK cell reactivity.

Neutrophils, like NK cells, are part of the innate immune system. They are the most abundant type of white blood cell in humans and play a key role in immunity by providing a first line of defense against pathogens. Neutrophil deficiency results in a profound immunodeficiency, leading to susceptibility to invasive bacterial infections (skin abscesses, pneumonia, and septicemia) and fungal infections ([@bib40]). For many years, the reported short lifespan of these cells, together with their potent antimicrobial functions, including phagocytosis and pathogen killing, restricted our understanding of their role in immunity to that of effector cells. It is now becoming increasingly clear that neutrophils also directly regulate adaptive immune responses during acute and chronic microbial infections ([@bib55]; [@bib64]; [@bib40]). We describe here a new immunoregulatory function of neutrophils in the guidance of NK cell maturation at steady state, in both humans and mice.

RESULTS
=======

NK cells in *Genista* mice are hyporesponsive
---------------------------------------------

We conducted an *N*-ethyl *N*-nitrosourea (ENU) mutagenesis program in mice, using a functional test to screen and identify genes involved in NK cell responsiveness. We selected a new mouse pedigree, *Genista*, with hyporesponsive NK cells ([Fig. 1, A and B](#fig1){ref-type="fig"}). This hyporeactivity in vitro was revealed by testing blood NK cell degranulation (i.e., surface exposure of CD107a) after stimulation with YAC-1 target cells ([Fig. 1, A and B](#fig1){ref-type="fig"}), and was accompanied by an impaired capacity to reject MHC-I--deficient splenocytes in vivo ([Fig. 1 C](#fig1){ref-type="fig"}). We used *Genista* splenocytes to analyze NK cell functions in more detail. The fraction of spleen NK cells responding to stimulation with YAC-1 cells was lower than that in WT mice, as demonstrated by determinations of the percentages of CD107a^+^ and IFN-γ^+^ NK cells, confirming our initial observations on blood ([Fig. 1 D](#fig1){ref-type="fig"}). *Genista* NK cells also responded less strongly than WT cells to stimulation of the NK1.1-, NKp46-, or NKG2D- and Ly49D-activating receptors ([Fig. 1 E](#fig1){ref-type="fig"} and not depicted). This hyporeactivity was not caused by down-regulation of the surface expression of these receptors ([Fig. 1 F](#fig1){ref-type="fig"} and not depicted). We then used phorbol 12-myristate 13-acetate (PMA) and ionomycin stimulation, which induces NK cell activation by bypassing cell surface receptor engagement. In these conditions, the vast majority of NK cells from *Genista* and WT mice responded similarly, both in terms of the percentage of responding NK cells and in terms of the ability of IFN-γ production per cell ([Fig. 1 G](#fig1){ref-type="fig"}). Thus, NK cell hyporeactivity of *Genista* mice was not caused by a permanent inability to degranulate or to produce cytokines.

![**An extrinsic factor contributes to NK cell hyporeactivity in *Genista* mice.** (A) Circulating NK cells from WT (top) or *Genista* mice (bottom) were stimulated for 4 h with YAC-1 target cells (right) or medium alone (left). Representative FACS histograms show NK1.1 and CD107a expression gated on NK1.1^+^ CD3^−^ cells. (B) Histograms representing the percentage of CD107a^+^ blood NK cells in WT or *Genista* mice upon stimulation with YAC-1 tumor cells. Data were pooled from three independent experiments. *n* = 3. (C) WT and β2mKO splenocytes were stained with two different doses of the fluorescent dye CFSE, mixed at a 1:1 ratio, and transferred into WT or *Genista* mice. The percentage of specific lysis of MHC-I--deficient cells corresponds to the ratio of the various populations before and 48 h after co-injection in the spleen. The experiment was performed twice. *n* = 2--3. (D and E) Splenocytes from WT (shaded bars) or *Genista* (open bars) mice were stimulated for 4 h with YAC-1 tumor targets or medium alone (D), or with anti-NK1.1, anti-NKp46, or isotype control mAb-coated plates (E). NK cell intracellular IFN-γ production (D and E, top) and degranulation (CD107a surface exposure; D and E, bottom) were measured by FACS on NK1.1^+^ CD3^−^ or NKp46^+^ CD3^−^ NK cells. Data were pooled from five independent experiments. *n* = 3--6. (F) Representative FACS profiles are shown for NK1.1, NKp46 surface expression, or isotype control mAb (IC, dashed) on WT (black) or *Genista* (gray) NK cells. (G) Splenic NK cells from WT (shaded bars) or *Genista* (open bars) mice were stimulated for 4 h with a mixture of PMA and ionomycin. Data show the frequencies of IFN-γ^+^ (left) or CD107a^+^ (right) NK cells among the total NK cell population in WT or *Genista,* or the amount of IFN-γ produced (MFI) per IFN-γ^+^ NK cells from WT or *Genista* (middle). MFI control values were calculated as the average of the IFN-γ mean fluorescence intensity (MFI) of IFN-γ^+^ NK cells from WT mice. (H) Purified WT spleen NK cells were transferred to WT (shaded bars) or *Genista* (open bars) hosts, as indicated. 7 d after transfer, the frequencies of IFN-γ--producing cells (left) and CD107a^+^ cells (right) among transferred WT NK cells were analyzed after stimulation with isotype control, anti-NK1.1, or anti-NKp46 mAb-coated plates. Experiments were repeated three times, with *n* = 2--4 transfer groups. Statistical significance was determined with a Mann-Whitney test. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20111908R_Fig1){#fig1}

NK cell defect in *Genista* mice is NK cell extrinsic
-----------------------------------------------------

We further dissected the mechanisms involved in the NK cell functional defect in *Genista* mice by determining whether the hyporesponsive phenotype was NK cell intrinsic or extrinsic. We transferred purified spleen NK cells from CD45.1^+^ WT donors into CD45.2^+^ *Genista* recipients or CD45.2^+^ WT recipients as a control and analyzed the reactivity of CD45.1^+^ WT donor cells 7 d after adoptive transfer. By stimulating NK1.1 and NKp46, we showed that WT NK cells transferred into *Genista* mice became hyporesponsive, displaying weaker responses than WT NK cells transferred into WT recipients ([Fig. 1 H](#fig1){ref-type="fig"}). The exposure of spleen WT NK cells to a *Genista* environment thus modified their responsiveness, demonstrating the involvement of an NK cell--extrinsic factor inducing NK cell hyporeactivity in *Genista* mice. In control, when stimulated by PMA and ionomycin, WT and Genista NK cells showed similar responsiveness ([Fig. 1 H](#fig1){ref-type="fig"}). It has recently been reported that splenic WT NK cells become hyporeactive when transferred into a MHC-I--deficient environment ([@bib24]; [@bib32]). We therefore assessed the expression of MHC class I molecules on the cell surface in *Genista* mice and found no difference between these mice and WT mice (unpublished data).

NK cell functions are impaired in the absence of neutrophils
------------------------------------------------------------

In studies performed in parallel to our NK cell--oriented screen, *Genista* mice were found to lack mature neutrophils (unpublished data). Analysis of the neutrophil compartment in the blood, spleen, and BM ([Fig. 2 A](#fig2){ref-type="fig"}), as well as in the liver, lungs, and lymph nodes (not depicted) showed that mature CD11b^+^Ly6G^high^ neutrophils were selectively absent from *Genista* mice. The NK cell hyporesponsive phenotype and the neutropenia were perfectly correlated in the colony of F2 animals obtained from the cross of *Genista* and WT mice. Genetic analysis identified a point mutation leading to an amino-acid substitution in the third zinc finger of the growth factor--independent-1 (Gfi-1) transcription factor in *Genista* mice (unpublished data). Gfi-1 has already been implicated in neutrophil development, as patients with mutations in *GFI-1* and *Gfi-1* KO mice are severely neutropenic ([@bib33]; [@bib63]). As previously observed in *Gfi-1* KO mice ([@bib33]), *Genista* mice display an accumulation of atypical myeloid precursors (Ly6G^low^, Ly6C^high^, CD11b^+^) in the BM, but we did not detect any major modification in the percentages of monocytes at the periphery ([Fig. 2, A and B](#fig2){ref-type="fig"}). The dissection of the monocyte compartment in the spleen of *Genista* mice showed normal numbers of inflammatory (CD115^+^, CD11b^+^, Ly6C^+^) and resident (CD115^+^, CD11b^+^, Ly6C^−^) monocytes as compared with WT ([Fig. 2 D](#fig2){ref-type="fig"}). In addition, percentages and numbers of DC subpopulations (conventional, plasmacytoid and CD8α) were comparable between WT and Genista in the spleen as well as in the cutaneous lymph nodes ([Fig. 2, C and D](#fig2){ref-type="fig"}; and not depicted). As Gfi-1 has also been described as a critical regulator of DC versus macrophage differentiation ([@bib50]), we sought to test the ability of BM cells from *Genista* mice to differentiate into DCs or macrophages in vitro. After 7 d in culture with M-CSF, *Genista* BM cells normally differentiated into BM-derived macrophages (BMMs) as judged by the up-regulation of F4/80 and CD11b ([Fig. 2 E](#fig2){ref-type="fig"}). The overnight stimulation with LPS induced a comparable up-regulation of the co-stimulatory molecules CD80, CD69, and CD86 at the surface of BMMs from WT and *Genista* ([Fig. 2 F](#fig2){ref-type="fig"}). In vitro DC differentiation assays lead to the generation of normal MHC-II^+^ CD11c^+^ BM-derived DCs (BMDCs) from WT and *Genista* BM cells ([Fig. 2 G](#fig2){ref-type="fig"}). Overnight activation with LPS showed a comparable up-regulation of CD80, CD69, CD86, and MHC-II on WT and *Genista*-derived BMDCs ([Fig. 2 H](#fig2){ref-type="fig"}). Collectively, these data show that, beside the lack of neutrophils, *Genista* mice do not display any major defect in NK cell accessory cells.

![***Genista* mice lack mature neutrophils.** (A and B) Representative FACS profiles of blood, spleen, and BM cells from WT or *Genista* mice stained with anti-CD11b and anti-Ly6G mAb (A) or anti-CD11b and anti-Ly6C mAb (B). Percentage of neutrophils (CD11b^high^ Ly6G^high^; A) and monocytes (CD11b^inter^ Ly6C^high^; B) are indicated. Data are representative of 6--10 independent experiments. *n* = 3--4. (C) Gating strategy for identification of DC populations in the spleen of WT (top) or *Genista* (bottom) mice. Live, single, CD11c^+^ Lin^−^ (CD3, CD19, NK1.1) spleen cells were plotted for CD11c and Siglec-H expression, with numbers indicating the percentage of pDCs (CD11c^+^ Siglec-H^+^). CD11c^high^ DCs were then subdivided in CD11b^high^ CD8α^−^ (conventional DCs) and CD11b^−^ CD8α^+^ (CD8α DCs) cells. Numbers indicate the percentage of each population. Data represent two experiments. *n* = 4. (D) Histograms representing the total numbers of neutrophils, monocytes, and DCs subpopulations in the spleen of WT (black) or *Genista* (white) mice. Live, single, Lin^−^ (CD3, CD19 NK1.1, Ly6G), CD115^+^ CD11b^+^ monocytes were further subdivided into inflammatory (Ly6C^+^) and resident (Ly6C^−^) monocytes. Experiments were performed two to five times. *n* = 3--4. Statistical significance was determined with a Mann-Whitney test. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001. (E) Representative FACS profiles of F4/80 and CD11b expression on BMMs from WT or *Genista* mice obtained after 8 d of in vitro differentiation of BM cells with GM-CSF. (F) CD80, CD69, and CD86 cell surface expression of BMMs from WT (top) or Genista (bottom) mice after overnight incubation with LPS (black histograms) or medium (filled gray histograms). (G) Representative FACS profiles of MHC-II and CD11c expression on BMDCs from WT or *Genista* mice obtained after 8 d of in vitro differentiation of BM cells with GM-CSF. (H) CD80, CD69, CD86, and MHC-II cell surface expression on BMDCs from WT (top) or Genista (bottom) after overnight incubation with LPS (black histograms) or medium (filled gray histograms). Experiments were performed twice. *n* = 3.](JEM_20111908_Fig2){#fig2}

*Gfi-1* is expressed in mouse NK cells, and might thus play a role in NK cell function. To address this question, we transferred purified spleen NK cells from Genista mice in WT recipients and monitored NK cell reactivity 7 d after transfer. In a WT environment, *Genista* NK cells became as responsive as host WT NK cells ([Fig. 3 A](#fig3){ref-type="fig"}), showing that the *Gfi-1* mutation in NK cells was not sufficient to affect their functional capacities at steady-state. We thus focused on the extrinsic factors present or absent in Genista mice that led to NK cell hyporesponsiveness. With the exception of their NK cell phenotype, the only apparent defect in *Genista* mice was neutropenia. In WT animals, immunohistological analysis of spleen and lymph node sections showed that the two cell types were localized in close proximity in the red pulp of the spleen or in the medulla next to the lymphatic vessels of the lymph nodes ([Fig. 4 A](#fig4){ref-type="fig"}). Furthermore, in vitro experiments assessing the ability of NK cells to form conjugates with neutrophils revealed the strong propensity of these two cell types to interact, as compared with the lack of conjugates detected between neutrophils and T or B cells ([Fig. 4 B](#fig4){ref-type="fig"}). We thus directly tested the hypothesis that neutrophils represented the NK cell extrinsic factor required to promote NK cell reactivity by using mAbs to deplete neutrophils from WT animals. As the use of neutrophil-depleting mAbs is still a matter of debate ([@bib17]), we performed these depletion experiments using anti-Gr1 (RB6-8C5) or anti-Ly6G (1A8) mAb. 6 d after mAb injection, RB6-8C5 treatment resulted in the depletion of neutrophils, but also of some monocytes (Ly6C^high^CD11b^low^), whereas 1A8 treatment had induced the selective depletion of neutrophils, as previously reported ([@bib17]; [Fig. 5 A](#fig5){ref-type="fig"}). Remarkably, the depletion of neutrophils by either treatment was sufficient to induce NK cell hyporeactivity in WT mice ([Fig. 5 B](#fig5){ref-type="fig"}). The intensity of the NK cell hyporesponsiveness in these conditions was lower than that in *Genista* mice, which is consistent with the lower severity of the neutropenia induced by mAb treatment than of that observed in *Genista* mice. Indeed, anti-Gr1 (RB6-8C5) or anti-Ly6G (1A8) mAb treatment induced neutrophil depletion in the blood and in the spleen, but not in the BM ([Fig. 5 C](#fig5){ref-type="fig"} and not depicted). A CD4 cell-depleting control mAb had no effect on NK cell function, indicating that the hyporeactivity induced by the injection of neutrophil-depleting mAb resulted directly from the lack of neutrophils, rather than from eventual side effects of the depleting antibody treatment ([Fig. 5, D and E](#fig5){ref-type="fig"}). Neutrophils are thus essential for NK cell function at steady state.

![***Genista* NK cells regain full reactivity in a WT environment.** Purified *Genista* spleen NK cells were transferred to WT or *Genista* (G) hosts, as indicated. 7 d after transfer, the frequency of IFN-γ--producing cells among transferred *Genista* NK cells (shaded bars) was analyzed after stimulation with isotype control, anti-NK1.1, and anti-NKp46 mAb-coated plates or a mix of PMA and ionomycin. The reactivity of NK cells from WT or *Genista* hosts was indicated as controls (open bars). Experiments were repeated three times. *n* = 2--3. Statistical significance was determined with a Mann-Whitney test. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20111908R_Fig3){#fig3}

![**NK cells and neutrophils are localized in the same areas of the spleen and the lymph nodes and form conjugates.** (A) Immunostaining on NKp46^iCre/wt^R26R^eYFP/wt^ spleen (top) or lymph node (bottom) sections at steady state showing neutrophils (anti-MMP9, red), NK cells (anti-GFP, green), B cells (anti-B220, blue), and the lymphatic vessels (Lyve-1, white in the lymph node image). Adjacent overlapping confocal images of spleen and lymph node sections were stitched to generate panoramic images. White arrowheads show contact between neutrophils and NK cells in the spleen. (B) Percentages of conjugates formed between neutrophils and NK cells (NK cells + Neutro), CD3^+^ T cells (T cells + Neutro), or CD3^−^ NK1.1^−^ cells (B cells + Neutro) after 10 min incubation together in vitro at 37°C. Data are representative of three independent experiments. Statistical significance was determined with a Mann-Whitney test. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20111908_Fig4){#fig4}

![**Neutrophils are essential for NK cell function at the steady state.** (A) Representative FACS profiles of spleen cells from Rat IgG2b- or RB6-8C5--treated mice (top) or, Rat IgG2a-, or 1A8-treated mice (bottom), stained with anti-Ly6C and anti-CD11b mAb. 1A8 is specific for Ly6G, whereas RB6-8C5 recognizes Ly6G and, with a lower affinity, Ly6C ([@bib26]). As RB6-8C5 recognizes a different epitope on Ly6C than the monoclonal anti-Ly6C (AL-21) antibody ([@bib52]), we used CD11b and Ly6C to monitor the percentage of both neutrophils (CD11b^high^ Ly6C^inter^, red circle) and monocytes (CD11b^inter^ Ly6C^high^, black circle). (B) 6 d after treatment, splenocytes from rat IgG2b- and RB6-8C5--treated (top) or, Rat IgG2a- or 1A8-treated mice (bottom), were stimulated by incubation for 4 h on anti-NK1.1, anti-NKp46, or isotype control mAb-coated plates or with a mixture of PMA and ionomycin. NK cell intracellular IFN-γ production was measured by FACS. Experiments were repeated 6--20 times. *n* = 3--6 mice per group. Statistical significance was determined in a Mann-Whitney test. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001. (C) Percentages of neutrophils (red circles) and monocytes (black circles) in the blood and the BM of rat IgG2a- or 1A8-treated mice. Data are representative of 6--10 independent experiments. *n* = 3--4. (D) 6 d after anti-CD4 antibody (GK1.5) or isotype control antibody (rat IgG2b) injection, the presence of CD4^+^ cells among CD3^+^ T cells was monitored in the spleen of rat IgG2b- or GK1.5-treated mice. (E) 6 d after depletion, splenic NK cells were stimulated for 4 h by incubation in plates coated with NK1.1, NKp46, or isotype control mAb, or with a mixture of PMA and ionomycin. The percentages of NK cells expressing intracellular IFN-γ are shown for control isotype-treated mice (shaded bars) and CD4-depleted mice (open bars). Experiments were performed twice. *n* = 2--3.](JEM_20111908_Fig5){#fig5}

Neutrophils are required for proper NK cell maturation
------------------------------------------------------

We next investigated the mechanisms by which neutrophils affect NK cell function by analyzing the effects of these cells on NK cell maturation, a process that is classically studied by monitoring the cell surface expression of CD27 and CD11b. Immature CD27^−^CD11b^−^ NK cells first acquire CD27 expression, to become CD27^+^CD11b^−^, and then acquire CD11b, yielding double-positive (DP) CD27^+^CD11b^+^ NK cells, which eventually lose their CD27 expression to become fully mature CD27^−^CD11b^+^ NK cells ([@bib34]; [@bib29]; [@bib13]). An investigation of these markers showed that NK cell maturation was severely affected in *Genista* mice, with most NK cells blocked at the DP stage ([Fig. 6 A](#fig6){ref-type="fig"}). An accumulation of DP NK cells was also observed in WT animals depleted of neutrophils ([Fig. 6 B](#fig6){ref-type="fig"}). Neutrophils therefore appeared to be required for the final stages of NK cell maturation, corresponding to the transition from the DP stage to the most mature CD27^−^CD11b^+^ stage. We characterized these maturation stages further by studying CD43, which is up-regulated during the down-regulation of CD27 in fully mature WT NK cells ([@bib34]; [@bib62]). The percentage of NK cells expressing CD43 was much lower in *Genista* mice than in WT mice ([Fig. 6 C](#fig6){ref-type="fig"}). These findings were confirmed in studies in which mAbs were used to deplete neutrophils in WT mice ([Fig. 6 D](#fig6){ref-type="fig"}). We interpreted the lower decrease in CD43 expression in WT mice depleted of neutrophils as compared with *Genista* mice as a consequence of the milder severity of the neutropenia induced by mAb treatment, as mentioned in the previous paragraph. Importantly, the percentage of CD43^+^ WT NK cells 7 d after transfer into *Genista* mice was also lower than that monitored after transfer into a WT recipient ([Fig. 6 E](#fig6){ref-type="fig"}). We investigated the relationship between this impaired maturation in the absence of neutrophils and the hyporesponsive phenotype of NK cells by comparing the responsiveness of CD43^−^ and CD43^+^ NK cells in WT mice. After the stimulation of NK1.1 and NKp46, both the percentage of IFN-γ^+^ NK cells and the mean fluorescence intensity of IFN-γ^+^ NK cells were lower in the CD43^−^ NK cell population than in the CD43^+^ NK cell population ([Fig. 6, F--H](#fig6){ref-type="fig"}). CD43-expressing NK cells thus responded more strongly than CD43^−^ NK cells in these conditions of stimulation. The lower percentage of CD43-expressing NK cells may thus account for the hyporeactivity of NK cells in neutropenic mice.

![**Neutrophils are required for terminal NK cell maturation.** (A and B) Representative FACS profiles of splenic NK cells stained with anti-CD27 and anti-CD11b mAb from WT and *Genista* mice (A) or 1A8, RB6-8C5, or isotype control mAb--treated mice (B). Experiments were performed 6--20 times. *n* = 3--6. (C) Representative FACS histograms of CD43 expression of splenic NK cells from WT (black line) or *Genista* (gray line). Tinted histogram shows isotype control staining. Data represent at least 20 independent experiments. (C--E) Percentages of splenic NK cells positive for CD43, for WT and *Genista* mice (C, right); isotype control-, 1A8-, or RB6-8C5--treated mice (D); or donor WT NK cells 7 d after transfer into WT or *Genista* hosts (E). Experiments were performed three to six times. *n* = 3--4. Statistical significance was determined in a Mann-Whitney test. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001. (F) Representative FACS profiles of splenic NK cells (gated on CD3^−^ NKp46^+^ or NK1.1^+^) from WT mice stained for CD43 and intracellular IFN-γ, 4 h after stimulation by incubation in isotype control, anti-NK1.1, or anti-NKp46 mAb-coated plates. (G) Frequencies of IFN-γ--producing splenic NK cells generated from CD43^+^ or CD43^−^ WT NK cells by stimulation on anti-NK1.1 or anti-NKp46 mAb-coated plates. (H) Amount of IFN-γ secreted per CD43^+^ (shaded bars) or CD43^−^ (open bars) NK cell in response to stimulation by incubation in anti-NK1.1 (top) or anti-NKp46 (bottom) mAb-coated plates. The MFI for IFN-γ of IFN-γ^+^ CD43^−^ NK cells was normalized with respect to that for IFN-γ^+^ CD43^+^ NK cells. Experiments were performed twice. *n* = 5--8. Statistical significance was determined in a Mann-Whitney test. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20111908_Fig6){#fig6}

NK cell homeostasis is modified in mice lacking neutrophils
-----------------------------------------------------------

In addition to their defective maturation, NK cells proliferated more in the absence of neutrophils. Indeed, the percentage of Ki67^+^ NK cells in *Genista* was significantly higher than that in WT mice, whereas there was no difference in the T and B cell compartments ([Fig. 7 A](#fig7){ref-type="fig"} and not depicted). This phenotype was neutrophil-dependent, as neutrophil depletion in WT mice led to the specific proliferation of NK cells ([Fig. 7 B](#fig7){ref-type="fig"}). This conclusion was also supported by experiments involving the adoptive transfer of WT NK cells. Indeed, 7 d after the transfer of CFSE-labeled WT NK cells into *Genista* recipients, 80 ± 13.2% of the WT NK cells had proliferated, whereas no proliferation was observed after transfer into WT recipients ([Fig. 7 C](#fig7){ref-type="fig"}). Given this extensive proliferation of WT NK cells after transfer into *Genista*, we hypothesized that the hyporeactive NK cell phenotype might be displayed only by new NK cells generated by the division of donor cells. We tested this hypothesis by comparing the responsiveness of undivided (CFSE^high^) WT NK cells after transfer into WT or *Genista* mice. We showed, by stimulation of NK1.1 and NKp46, that there was a change in NK cell responsiveness after transfer of WT cells in *Genista* mice, even for NK cells that did not divide ([Fig. 7 D](#fig7){ref-type="fig"}), ruling out the possibility that NK cell hyporeactivity in the absence of neutrophils was caused by NK cell proliferation alone. Nevertheless, NK cells that had divided (CFSE^diluted^) had lower levels of activity than undivided (CFSE^high^) cells ([Fig. 7 D](#fig7){ref-type="fig"}). NK cell proliferation in the absence of neutrophils was therefore associated with NK cell hyporeactivity, but did not fully account for the phenotype. The higher level of NK cell proliferation in *Genista* mice was not associated with an increase in the number of NK cells. Indeed, the overall percentages of NK cells in the blood and spleen were unchanged (blood, 3.71 ± 0.85% for WT and 3.05 ± 1.04% for *Genista*, P = 0.3417; spleen, 2.98% ± 0.87 for WT and 2.4% ± 1.01 for *Genista*, P = 0.3002), whereas it was significantly reduced in the BM of *Genista* mice as compared with WT mice (BM, 0.93 ± 0.35 for WT and 0.49 ± 0.33% for *Genista*, P = 0.0021), suggesting that NK cell proliferation was accompanied by a decrease in NK cell survival. Indeed, *Genista* NK cells displayed higher levels of cell death in vitro than WT NK cells, and this difference was not abolished by overnight treatment with IL-15 or IL-2 ([Fig. 7 E](#fig7){ref-type="fig"}). Thus, in mice lacking neutrophils, NK cells displayed hyperproliferation and poor survival and were blocked at an immature stage associated with hyporesponsiveness.

![**Higher rates of proliferation and poorer survival of NK cells in the absence of neutrophils.** (A and B) Representative FACS profiles of splenic NK cells from WT and *Genista* (A, or isotype control-- and 1A8-treated mice (B) stained with anti-NK1.1 and anti-Ki67 mAb. Data a representative of three independent experiments. *n* = 3--4. (C and D) CFSE-labeled CD45.1^+^ WT spleen NK cells (donor) were transferred into CD45.2^+^ WT or *Genista* hosts for 7 d. (C) Representative FACS profiles show the percentage of donor WT NK cells (rectangle) after transfer into WT (top left) or *Genista* (top right) mice. Histograms of CFSE expression gated on donor CD45.1^+^ WT NK cells after transfer into WT (bottom left) or *Genista* (bottom right) mice. (D) 7 d after transfer into WT (left) or *Genista* (right) mice, the frequency of undivided (CFSE^high^) or divided (CFSE^diluted^) donor WT NK cells producing IFN-γ in response to stimulation with isotype control, anti-NK1.1, or anti-NKp46--coated plates was determined. (top) Representative FACS profile upon NK1.1 activation. (bottom) Statistical comparison of NK cell responsiveness in undivided (CFSE^high^) and divided (CFSE^diluted^) donor NK cells. Experiments were performed three times. *n* = 2--4. (E) Representative FACS profiles of WT or Genista NK cells (gated on CD3^−^ NKp46^+^ or NK1.1^+^) stained with anti--Annexin V and propidium iodine (Pi) after overnight incubation with medium, 1,000 U/ml IL-2 or 15 ng/ml IL-15. (F) Frequencies of Pi^+^ NK cells from WT (shaded bars) or *Genista* (open bars) mice after overnight incubation with medium, 1,000 U/ml IL-2 or 15 ng/ml IL-15. Experiments were repeated three times. *n* = 7--10. Statistical significance was determined in a Mann-Whitney test. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.005.](JEM_20111908_Fig7){#fig7}

Impaired NK cell maturation and function in neutropenic patients
----------------------------------------------------------------

These data revealing a new role for neutrophils in NK cell function in the mouse prompted us to assess NK cell maturation and function in patients suffering from neutropenia. Patients with severe congenital neutropenia (SCN) have no terminally differentiated neutrophils because of the blockage of maturation at the promyelocyte stage in the BM ([@bib21]; [@bib36]). Mutations of the neutrophil *ELANE* gene, encoding the serine protease elastase, are the most common cause of SCN ([@bib5]; [@bib30]), but mutations targeting the gene involved in *Wiskott-Aldrich syndrome* ([@bib1]; [@bib19]), *HCLS1-associated protein X-1* ([@bib37]), *G6PC3* ([@bib7]), or *GFI-1* ([@bib49]) have also been described. We analyzed a cohort of 22 SCN patients, 11 of whom had a mutation in *ELANE*; the mutations in the other 11 patients were unidentified ([Table 1](#tbl1){ref-type="table"}). Some of them were treated with granulocyte colony-stimulating factor (G-CSF) to increase neutrophil counts. Blood NK cell counts were similar in SCN patients and healthy controls ([Fig. 8 A](#fig8){ref-type="fig"}), but using CD56 down-regulation as a marker of terminal NK cell maturation, the frequency of CD56^bright^ NK cells was higher in SCN patients than in controls, indicating that NK cells of SCN patients were less mature ([Fig. 8 B](#fig8){ref-type="fig"}). We assessed the possible functional impairment of NK cells from SCN patients, by monitoring the percentage of IFN-γ^+^ NK cells generated in response to stimulation with K562 tumor target cells or antibody-coated P815 cells, as a means to evaluate antibody-dependent cell-mediated cytotoxicity (ADCC). Under both types of stimulation, the percentage of responding NK cells was much lower in SCN patients than in healthy controls ([Fig. 8, C and D](#fig8){ref-type="fig"}). This hyporesponsive phenotype was confirmed by determining the percentage of lysed target cells ([Fig. 8, E--F](#fig8){ref-type="fig"}). NK cells from patients lacking neutrophils thus displayed a maturation and functional defect similar to that observed in neutropenic mice, demonstrating that the key role of neutrophils in NK cell maturation and function is conserved between humans and mice.

###### 

Patient characteristics

  Patient   Age    Sex   Mutations          Neutrophil count   NK cell count   Treatment with G-CSF
  --------- ------ ----- ------------------ ------------------ --------------- ----------------------
            *yr*                            *cells/µl*         *cells/µl*      
  1         24     F     SCN ELANE          860                136             \+
  2         2      F     SCN ELANE          58                 121             \+
  3         3      F     SCN ELANE          ND                 167             −
  4         34     F     SCN ELANE          ND                 210             −
  5         5      F     SCN ELANE          1,400              267             \+
  6         5      F     SCN ELANE          2,500              285             \+
  7         2      F     SCN ELANE          100                483             \+
  8         30     F     SCN ELANE          1,300              198             −
  9         33     F     SCN ELANE          360                85              −
  10        3      M     SCN ELANE          590                186             −
  11        36     F     SCN ELANE          60                 144             −
  12        21     F     SCN unidentified   4,624              154             \+
  13        4      F     SCN unidentified   425                258             −
  14        19     F     SCN unidentified   1363               200             \+
  15        9      F     SCN unidentified   264                184             −
  16        4      M     SCN unidentified   440                112             −
  17        0.4    F     SCN unidentified   920                240             −
  18        0.5    M     SCN unidentified   490                87              −
  19        60     M     SCN unidentified   540                29              −
  20        3      M     SCN unidentified   230                313             −
  21        22     F     SCN unidentified   170                75              −
  22        1      F     SCN unidentified   460                605             −
  23        1      F     AIN                0                  384             −
  24        1.2    F     AIN                370                943             −
  25        3      F     AIN                1010               104             −
  26        3      F     AIN                1530               276             −
  27        5      F     AIN                160                207             −
  28        2      M     AIN                550                339             −

The SCN patients (*n* = 22; median age = 5 yr; range = 0.4--60) and AIN patients (*n* = 6; median age = 2.6 yr; range = 1--5) described were analyzed and compared with healthy control individuals (*n* = 25; median = 30 yr; range = 22--55). ND, not determined.

![**Impaired NK cell maturation and function in patients with SCN.** Total NK cell (CD3^−^CD56^+^; A) and percentages of CD56^bright^ NK cells (B) in peripheral blood of healthy controls (black squares), SCN patients not treated with G-CSF (open circles) or SCN patient treated with G-CSF (black diamonds). (C-F) PBMCs from healthy control individuals (black squares), SCN patients not treated with G-CSF (open circles), or SCN patient treated with G-CSF (black diamonds) were stimulated for 4 h with K562 target cells (C--E) or antibody-coated cells (ADCC; D-F) at an effector/target ratio of 5:2 and 50:1, respectively. Frequencies of IFN-γ--producing NK cells (C and D) and NK cell cytotoxic activity (E and F) were determined by FACS. Statistical significance was determined in a Mann-Whitney test. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.005.](JEM_20111908_Fig8){#fig8}

SCN is currently treated by G-CSF injections, which increase the rate of granulopoiesis and result in the mobilization of neutrophils to the periphery. Neutrophil count restoration is variable among patients and depends on the dose of G-CSF used ([@bib21]). In some patients, these neutrophils have been shown to be only partially functional ([@bib22]). Some studies have indicated a potential role of G-CSF in NK cell function ([@bib41]). We therefore compared the reactivity of NK cells between SCN patients with and without G-CSF treatment. NK cell reactivity did not differ between G-CSF--treated and untreated patients ([Table 1](#tbl1){ref-type="table"}; and [Fig. 8, C--F](#fig8){ref-type="fig"}). An increase in the frequency of CD56^bright^ cells was also observed in SCN patients treated with G-CSF compared with controls ([Fig. 8 B](#fig8){ref-type="fig"}). Thus, G-CSF treatment is not sufficient to restore NK cell reactivity and maturation in SCN patients.

The BM is the main reservoir for neutrophils at steady state. We found that neutrophils were still present in the BM of neutrophil-depleted WT mice in which NK cells were hyporesponsive ([Fig. 2 A](#fig2){ref-type="fig"}; and [Fig. 5, B and C](#fig5){ref-type="fig"}). In this model, the NK cell hyporesponsiveness was milder than that in *Genista* mice, which lack neutrophils in both the BM and the periphery, suggesting a contribution from, but not a requirement for, BM neutrophils ([Fig. 1, E and F](#fig1){ref-type="fig"}; and [Fig. 5 B](#fig5){ref-type="fig"}). We therefore investigated whether BM neutrophils or neutrophils circulating at the periphery were required for NK cell function in humans. We addressed this question by analyzing a second cohort of patients with autoimmune neutropenia (AIN; [Table 1](#tbl1){ref-type="table"}). AIN patients have circulating antibodies targeting neutrophils, leading to a lack of mature neutrophils at the periphery. Unlike SCN patients, AIN patient display normal neutrophil development in the BM. In AIN patients, NK cell counts were not statistically different from the control individuals ([Fig. 9 A](#fig9){ref-type="fig"}), whereas NK cell maturation was affected with a trend toward an accumulation of immature CD56^bright^ NK cells ([Fig. 9 B](#fig9){ref-type="fig"}). Despite the high variability among individuals and the limited number of AIN patients, NK cells from these patients were also less reactive to antibody-coated cells, as shown by the percentage of IFN-γ^+^ cells ([Fig. 9 C](#fig9){ref-type="fig"}) or direct target cytotoxicity ([Fig. 9 D](#fig9){ref-type="fig"}). A down-regulation of NK cell reactivity in response to K562 target cells was also observed in blood samples from AIN patients ([Fig. 9, E and F](#fig9){ref-type="fig"}), but this trend was not statistically significant for IFN-γ secretion, probably because of the small size of our cohort of AIN patients. Thus, despite the presence of neutrophils in the BM, peripheral NK cells from AIN patients were hyporesponsive, like NK cells from SCN patients, although the observed defect was milder. Interestingly, one of the AIN patients recovered from neutropenia 8 mo after the first analysis. This increase in neutrophil counts was associated with the recovery of NK cell functions ([Fig. 9, G and H](#fig9){ref-type="fig"}). Altogether, these results indicate that neutrophils contribute to NK cell development and functions in humans.

![**Impaired NK cell maturation and function in patients with AIN.** Total NK cell (CD3^−^CD56^+^; A) and percentages of CD56^bright^ NK cells (B) in peripheral blood of healthy control individuals (black squares) and AIN patients (open circles). (C--F) PBMCs from healthy controls (black squares) or AIN patients (open circles) were stimulated for 4 h with K562 target cells (C--E) or ADCC (D--F) at an effector/target ratio of 5:2 and 50:1, respectively. (C and D) Frequencies of IFN-γ--producing NK cells and (E and F) NK cell cytotoxic activity were measured by FACS. Statistical significance was determined in a Mann-Whitney test. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.005. (G) Representation of the neutrophil count (cells/microliter) in peripheral blood of AIN patient \#25 during neutropenia and after remission. Dashed line indicates the neutropenia threshold of 1,500 neutrophils/µl. (H) PBMCs from AIN patient \#25 during neutropenia (top) or after remission (bottom) were stimulated for 4 h with K562 target cells, ADCC, or medium. FACS profiles show IFN-γ^+^ NK cells among (CD3^−^ CD56^+^) NK cells. Percentages of IFN-γ^+^ NK cells are indicated.](JEM_20111908_Fig9){#fig9}

DISCUSSION
==========

We report here a new role for neutrophils as nonredundant regulatory cells ensuring the terminal maturation of NK cells and the acquisition of their full effector functions in steady-state conditions in both humans and mice.

Using a forward genetic approach we identified a mutant mouse, *Genista*, with hyporesponsive NK cells coupled to neutropenia. The hyporeactivity of *Genista* NK cells was observed in vivo against MHC-I--deficient splenocytes and in vitro upon stimulation with the tumor cells YAC-1 or after triggering of the NK1.1, NKp46, NKG2D, and Ly49 receptors. The surface expression of these receptors was unchanged, suggesting that a wide range of activating pathways coupled to various signaling adaptor molecules, such as FcRγ, DAP12, and DAP10, are affected in NK cells in the absence of neutrophils. The hyporesponsive phenotype was associated with a block in NK cell maturation before the up-regulation of cell surface CD43, a marker that accompanies NK cell responsiveness in WT mice.

In humans, we studied several subtypes of neutropenia with distinct clinical profiles and pathophysiology backgrounds. First, we analyzed SNC patients. 11 of them presented a mutation in the *ELANE* gene, whereas the genetic etiology was unidentified for the others. Like in the mouse model, NK cell maturation and responsiveness were affected in these patients. These results first established the conservation of the major role of neutrophils on NK cell functions across species. In addition, they also indicated that the mechanism of NK cell/neutrophil cellular cooperation was independent of the gene involved in neutropenia (*Gfi-1* in the mouse, *ELANE* in humans). The role of neutrophils in NK cell biology was further confirmed by the depletion of neutrophils with antibodies in WT mice and by studying AIN patients. In these patients, AIN is transient and is related to the presence of antibodies directed against epitopes of neutrophil membranes: NA1a, b, and c in most cases ([@bib10]). In conclusion, whatever the cause of the neutropenia is, the phenotype of NK cell hyporesponsiveness is present both in humans and in mice.

Importantly, one of the AIN patients of our cohort spontaneously resolved his neutropenia and NK cell functions were restored in parallel, reinforcing the intimate link between the two cell subsets. In contrast, no restoration of NK cell reactivity was detected in patients responding to G-CSF treatment by an increase in neutrophil count (above the threshold of 1,500 cells/µl). Similarly, 1 wk of G-CSF injections in *Genista* mice mobilized immature, Ly6G^−^ neutrophils to the periphery, but did not restore NK cell function (unpublished data). Thus, neutrophils that are induced by G-CSF treatment do not acquire the capacity to potentiate NK cell function, prompting further dissection of the differences between these neutrophil populations and normal neutrophils. Along this line, it was shown in some patients that G-CSF treatment reverses neutropenia without correcting all the functional deficiencies of neutrophils ([@bib22]). This issue remains to be revisited in larger cohorts of SCN patients with different genetic etiology.

NK cell homeostasis was also modified in mice lacking neutrophils. We observed an increased sensitivity to cell death ex vivo and an increased proliferation of NK cells in vivo. As we did not observe any accumulation of NK cells in neutropenic mice, it could indicate that NK cell proliferation is counterbalanced in vivo by NK cell death. NK cell proliferation induced in neutropenic mice differed from NK cell homeostatic proliferation occurring in a lymphopenic environment, which is associated with higher NK cell reactivity ([@bib56]). We have shown in transfer experiments of WT NK cells in neutropenic recipients that the acquisition of the hyporesponsive NK cell phenotype did not require proliferation, even if hyporesponsiveness was increased in proliferating cells. It is possible that NK cells and neutrophils make use of the same trophic factors and that the absence of neutrophils modifies the concentration of these molecules, with an impact on the NK cell compartment. However, we do not favor this hypothesis because a large number of neutrophils remained present in the BM when peripheral neutrophils were depleted in mAb-treated WT animals and in AIN patients. In the two species, the presence of BM neutrophils was not sufficient to promote NK cell functions even if, in these conditions, the NK cell defect was milder. These findings support a model in which neutrophils are mandatory for NK cell maturation from the CD43^−^ CD27^+^CD11b^+^ toward the CD43^+^ CD27^−^CD11b^+^ stage. A similar block in NK cell maturation has been previously reported in T-bet KO mice ([@bib57]; [@bib54]), but we did not detect any change in T-bet or eomesodermin expression by intracellular staining on *Genista* NK cells as compared with WT (unpublished data). The lack of neutrophils may induce an increased turnover of NK cells that cannot reach a mature functional state. Neutrophil-induced NK cell maturation may occur not only in the BM, in which NK cells develop, but also at the periphery, suggesting a constant requirement for neutrophils, to promote NK cell function. Along this line, we also showed that spleen NK cells from neutropenic *Genista* mice reacquire a functional phenotype 7 d after transfer in a WT environment.

To further dissect the mechanisms at work in this cellular cooperation, we described direct NK cells/neutrophils interactions in vitro and in vivo. The two cell subsets are located in the same compartments in lymphoid organs (spleen and LN) of uninfected mice and have a high propensity to form conjugates in vitro. Yet, the short-term co-culture of purified WT neutrophils with *Genista* NK cells was not sufficient to restore NK cell function (unpublished data). In addition, we were not able to restore NK cell functions in Genista mice by injecting purified WT BM neutrophils. However, despite repeated injections (every day for 6 d), the number of neutrophils in recipient mice remained well below that observed in WT mice (unpublished data). Both in vivo and in vitro, these experimental conditions are limited by the fragility and very short half-life of neutrophils. Therefore, these negative results do not rule out a direct role of neutrophils on NK cells. Alternatively, neutrophils might cooperate with a third cell type to potentiate NK cell activity. Along this line, cross talk between human neutrophils and NK cells has been reported after stimulation with LPS and IL-2 or IL-15/IL-18 ([@bib14]). This crosstalk involves 6-sulfo LacNAc^+^ DCs (slanDC), through both direct cell--cell interactions dependent on CD18, ICAM-1, and ICAM-3, and indirect interactions mediated by cell-derived cytokines, such as IL-12 and IFN-γ ([@bib14]). It is impossible to address the role of slanDC in vivo*,* as no counterparts of these cells have been identified in the mouse ([@bib14]). Interestingly, we previously found that CD18 on NK cells was required for NK cell maturation and function ([@bib15]). CD18 associates with CD11a, CD11b, and CD11c proteins to generate functional integrin receptors ([@bib39]). CD11/CD18 integrins bind to several receptors, including ICAM-1, ICAM-2, ICAM-3, inactivated C3b, and fibrinogen ([@bib39]). We investigated the involvement of ICAM-1 in the acquisition of NK cell functions. In ICAM-1--deficient mice, NK cell functions, assessed by determining CD107a exposure and IFN-γ production upon stimulation with YAC-1 target, NK1.1, and NKp46, was found to be similar to that in WT controls (unpublished data). Moreover, NK cell maturation was not affected in ICAM-1 KO mice, as shown by the expression of CD43, CD11b, and CD27 markers (unpublished data). Thus, ICAM-1 is not required for neutrophil-induced NK cell maturation, indicating that if CD18 is involved in this process in vivo, it can act through interactions with other ligands. The mechanisms at work in steady-state conditions may therefore at least partially differ from the NK-neutrophil-slanDC "ménage à trois" described as being initiated by neutrophil activation with human cells in vitro ([@bib14]).

Neutrophils have been described as critical activators of NK cells in mice, acting in an IL-18/MyD88-dependent manner against *Legionella pneumophila* infection ([@bib55]), supporting our data on the implication of neutrophils in NK cell reactivity. Yet, our present findings extend the role of these cells to steady-state conditions in humans and mice. In addition, the mechanisms involved during the course of this microbial infection are different from those at work at steady state, as we previously showed that NK cells in MyD88 KO mice display no defect in IFN-γ secretion upon stimulation of NK1.1, NKp46, or YAC-1 ([@bib12]), in contrast to the situation in mice lacking neutrophils.

Altogether, our data thus rule out the requirement of signaling via IL-18--dependent and other MyD88-dependent receptors in neutrophil-induced NK cell maturation at steady state.

It has been reported recently that a subset of Ly6C^−^ myeloid-derived suppressor cells that develop during chronic inflammation associated to tumors was capable of impairing NK cell development and function ([@bib23]). We observed an increased number of Ly6C^−^ atypical myeloid precursors in the BM of *Genista* mice ([Fig. 2, A and B](#fig2){ref-type="fig"}). We do not know if these cells are related to those appearing in such pathological conditions, but we cannot exclude that they could contribute in the induction of the NK cell phenotype in *Genista* mice. However, such an accumulation is not observed in the BM of WT mice depleted of neutrophils, excluding their major role in the function on NK cells that we report here.

NK cells cooperation with monocytes/macrophages and DCs is well documented ([@bib16]; [@bib4]; [@bib61]; [@bib38]; [@bib45]; [@bib58]; [@bib6]; [@bib54]). Our present study reveals a novel aspect of the role of neutrophils on NK cells. The possibility of a reciprocal cross talk between the two cell types could be envisaged. Along this line, it has been reported that IFN-γ regulates survival of neutrophils in the context of *Mycobacterium tuberculosis* infections ([@bib43]). As NK cells are important producers of IFN-γ, it would be interesting to analyze neutrophils in NK-deficient mice both in steady-state and inflammatory conditions.

Finally, high incidence of myelodysplasia and acute myeloid leukemia has been reported in neutropenic patients ([@bib20]; [@bib53]). Risk factors for myelodysplasia and acute myeloid leukemia include the severity of neutropenia and the exposure of high doses of G-CSF ([@bib20]). In light of the data presented here, the defect in NK cell immunosurveillance in these patients might also impact on the development of these malignancies. Thus, our data not only reveal a new regulatory pathway in innate immunity, but also provide insight into the previously unappreciated role of NK cell functional deficiency in patients suffering from neutropenia-associated diseases. This should prompt a reanalysis of immune deficiencies involving neutrophils or NK cells to further unravel the role of the cross talk between these cells in immunity.

MATERIALS AND METHODS
=====================

### Mice and ENU mutagenesis.

The ENU mutagenesis leading to the isolation of the *Genista* pedigree was performed in the C57BL/6J (Charles River) background ([@bib27]). C57BL/6J CD45.1 mice were purchased from Charles River. C57BL/6J, *Genista*, and NKp46^iCre/wt^R26R^eYFP/wt^ ([@bib44]) mice were bred and maintained under specific pathogen--free conditions at the animal facility of CIML and the Centre d'Explorations Physio-pathologiques Avancées RIO platform in Marseilles. Experiments were conducted in accordance with institutional guidelines for animal care and use. Protocols were approved by the Direction Départementales des Services Vétérinaires des Bouches du Rhône.

### Antibodies.

The monoclonal antibodies used for flow cytometry and activation were: purified anti-NKp46 (29A1.4) conjugated with Alexa Fluor 647 or PE; anti-NK1.1 (PK136) conjugated with APC and PerCP-Cy5.5 and purified; anti-CD3 (145-2C11) conjugated with PE, FITC, PerCP-Cy5.5, and APC; anti-CD11b (M1/70) conjugated with V450; anti-CD27 (LG.3A10) conjugated with PE; anti-CD43 (S7) conjugated with PE or FITC; anti-CD45.1 (A20) conjugated with Pacific blue and Pe-Cy7; CD45.2 (104) conjugated with PerCP; anti--IFN-γ (XMG1.2) conjugated with APC and Alexa Fluor 647; anti-CD107a (1D4B) conjugated with FITC; Annexin V-FITC; anti-CD80 (16-10A1); anti-CD86 (GL1); anti-CD69 (H1.2F3); anti--mI-A/I-E (M5/114.15.2); and anti-CD19 (AD3). All antibodies were purchased from BD. Anti-Ki67 (20Raj1) antibody conjugated with PE and anti-CD45.2 (104) antibody conjugated with Alexa Fluor 700 were purchased from eBioscience. Anti-CD115 (AFS98) was purchased from BioLegend. Samples were analyzed with FACSCanto II, LSRII (BD), and FlowJo software (Tree Star).

### In vitro NK cell stimulation.

Blood lymphocytes isolated with a Lympholyte gradient for mammalian cells (TEBU) or from spleen cell suspensions after red blood cell lysis were incubated with YAC-1 tumor targets or dispensed into a 96-well 2HB Immulon plate coated with purified antibody against NK1.1 (25 µg/ml), NKp46 (10 µg/ml), or isotype controls. Cells were activated in the presence of monensin (GolgiStop; BD), GolgiPlug (BD), and anti-CD107a antibody conjugated with FITC (where indicated) in complete medium (RPMI-1640 \[Invitrogen\] supplemented with 10% fetal calf serum, 1 mM sodium pyruvate, 10 mM Hepes, 100 U/ml penicillin, and 100 µg/ml streptomycin). As a positive control, we stimulated the cells with a mixture of 200 µg/ml PMA and 5 µg/ml ionomycin. The cells were incubated for 4 h at 37°C, and then cell surface staining was performed. For intracellular IFN-γ staining, cells were fixed with 2% paraformaldehyde (PFA) and permeabilized with Perm/Wash solution (BD).

### In vivo rejection of target cells.

This method for the quantitative assessment of in vivo killing was adapted from a method described in a previous study ([@bib47]). In brief, splenocytes from WT or β2mKO mice were labeled with 2 and 0.2 µM CFSE (Invitrogen), respectively, and mixed at a 1:1 ratio. The ratio of the various populations before injection was determined by FACS analysis and compared with the ratio in the spleen 48 h after injection.

### Adoptive transfer of NK cells.

Splenocyte suspensions from CD45.2^+^ WT or *Genista* donor mice were obtained by mechanical disruption of the spleen of the mouse, in complete medium, on a cell strainer with 70-µm pores (BD). Red blood cells were lysed in RBC lysis buffer (eBioscience). The preparation was then enriched in NK cells by negative depletion with mAbs against CD4, CD5, CD8, Ter119, and IA/IE, as previously described ([@bib13]). NK cell purity was ∼85%. Donor NK cells were labeled with 1 µM CFSE (Invitrogen) and 2--3 × 10^6^ NK cells/mouse were injected i.v. into WT or *Genista* CD45.1^+^ recipient mice.

### In vitro DC and macrophage differentiation.

BM cells were flushed from tibiae and femurs of WT or *Genista* mice and cultured in complete RPMI medium supplemented with M-CSF at 10 ng/ml. Adherent BMMs were obtained after 7 d in culture. BMDCs were obtained and cultured, as previously described ([@bib31]). 7 d after culture of BMDCs or BMMs, 10 ng/ml of LPS was added to the culture and up-regulation of co-stimulatory molecule expression was monitored by FACS.

### In vivo depletion.

Neutrophil depletion was achieved by injecting 500 µg of 1A8/mouse (BioXCell), 100 µg of RB6-8C5/mouse (BioXCell) or isotype controls i.p. into mice on days 0 and 2. CD4^+^ T cells were depleted by two i.p. injections of 200 µg of GK1.5/mouse (BD) on days 0 and 1. The analysis was performed on day 6.

### Conjugate assay.

The BM was flushed from the tibia and femur of WT mice and separated on a 65% Percoll (GE Healthcare) gradient. The pellet was retained and the red blood cells were lysed in RBC lysis buffer (eBioscience). The resulting preparation contained \>80% neutrophils, which were then stained with PKH26 (Sigma-Aldrich), according to the manufacturer's protocol. Purified neutrophils were then incubated at a 1:1 ratio, with WT splenocytes previously stained with anti-NK1.1 and anti-CD3 antibodies. After 10 min at 37°C, cells were fixed with 1% paraformaldehyde and analyzed by FACS. The conjugates correspond to PKH26^+^ NK1.1^+^ CD3^−^ cell doublets.

### Immunostaining.

Organs were harvested and fixed by incubation in 0.05 M phosphate buffer supplemented with 0.1 M [l]{.smallcaps}-lysine, pH 7.4, 2 mg/ml NaIO~4~, and 10 mg/ml paraformaldehyde for 12 h. They were then washed in phosphate buffer and dehydrated by incubation in 30% sucrose in phosphate buffer. Spleens from NKp46^iCre/wt^R26R^eYFP/wt^ mice were snap-frozen in Tissue-Tek (Sakura Finetek). We cut 20-µm frozen sections and stained them as previously described ([@bib3]). Anti-B220 (RA3-6B2) antibody conjugated with Alexa Fluor 647 (BD), anti-MMP9 rabbit polyclonal antibody (Abcam) detected with a Pacific blue--conjugated anti--rabbit antibody (Life Technologies), anti-Lyve1 rabbit polyclonal antibody (Acris GmbH) detected with A647-conjugated anti--rabbit antibody (Invitrogen), and an anti-GFP Alexa Fluor 488 antibody (Invitrogen) were used for staining. Immunofluorescence confocal microscopy was performed with a Leica SP5 confocal microscope. Separate images were collected for each fluorochrome and overlaid to obtain a multicolor image. Final image processing was performed with Imaris software (Bitplane) and Photoshop software (Adobe).

### Patients and controls.

PBMCs were isolated by the centrifugation on Ficoll (EuroBio) gradients of whole blood samples obtained from healthy volunteer donors and from the SCN and AIN patients described in [Table 1](#tbl1){ref-type="table"}. Patients were recruited from departments of Pediatric Hematology of Trousseau Hospital (Paris), Necker Enfants Malades Hospital (Paris), and La Timone Hospital (Marseille) if they present a chronic neutropenia classified according to the literature ([@bib21]). Patients with congenital neutropenia were included in the French Severe Chronic Neutropenia cohort, which has been reported elsewhere ([@bib20]). The patients or their parents provided their written informed consent for genetic testing and inclusion in the register approved by the Commission Nationale de l'Informatique et des Libertés (number 01--1084). Genomic DNA was extracted from blood with standard procedures and *ELANE*, *G6PC3*, *HAX1*, *WASP*, and *SBDS* mutations were screened ([@bib5]; [@bib21]). In addition to patients with congenital neutropenia, AIN patients, diagnosed if autoantibodies against neutrophils were detected ([@bib11]), were also included in the study.

### In vitro activation of human NK cells.

PBMCs were incubated in the presence of GolgiStop (1/1500; BD) with MHC class I^−^ human erythroleukemic K562 target cells or P815 mouse mastocytoma cells coated with rabbit anti--mouse lymphocyte antibodies (BioValley). After incubation for 4 h at 37°C, cells were stained with anti-CD3 (SK7), PercPCy5.5-conjugated antibody (BD) and with anti-CD56 (NKH-1) APC-conjugated antibody (Immunotech). Intracellular IFN-γ staining was performed after fixation in 2% paraformaldehyde and permeabilization in Perm/Wash solution (BD). For NK cytotoxicity analysis, K562 or P815 cells incubated with rabbit anti--mouse lymphocyte antibodies were stained with 0.5 µM CFSE (Invitrogen) for 10 min, washed, and incubated with PBMCs at a 50:1 ratio. After 4 h at 37°C, cells were stained with 2.5 µg/ml propidium iodide (Invitrogen) and analyzed by flow cytometry.

### Statistics.

All P values were determined with Prism software (GraphPad Software Inc.) for nonparametric unpaired or paired tests (two-tailed), as indicated. We considered p-values \<0.05 to be significant and the degree of significance is indicated as follows: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.
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